Navigation Links
Previously unknown immune cell may help those with Crohn's and colitis
Date:11/3/2008

The tonsils and lymphoid tissues in the intestinal tract that help protect the body from external pathogens are the home base of a rare immune cell newly identified by researchers at Washington University School of Medicine in St. Louis. The researchers indicate that the immune cells could have a therapeutic role in inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis.

Their report will appear in an upcoming issue of the journal Nature and is currently available through advanced online publication.

"These cells have an anti-inflammatory effect," says the article's lead author Marina Cella, M.D., research associate professor of pathology and immunology. "In the gut, we have beneficial bacteria, and it's important that the body does not recognize them as something detrimental and start an inflammatory reaction, which could ultimately promote tissue damage and inflammatory or autoimmune diseases such as IBD. The cells we've discovered are important for keeping such harmful inflammatory processes in check."

The cells are a type of natural killer (NK) cells, which are white blood cells classically known to eliminate tumor cells and cells infected by viruses. Because of their killer tendencies, NK cells are carefully controlled and don't act until they receive the right signal.

Some of the signals that activate the newly discovered cells are the same signals that turn on a different immune cell with strong inflammatory properties that can promote cell death and tissue damage if chronically active. But the anti-inflammatory cells, termed NK-22 cells, that the Washington University researchers discovered have the opposite effect they promote cell proliferation and wound healing.

"That finding suggests that these cells play a role in maintaining a balance in the immune system between inflammatory processes and anti-inflammatory processes," says coauthor Jason Mills, M.D., Ph.D., assistant p
'/>"/>

Contact: Gwen Ericson
ericsong@wustl.edu
314-286-0141
Washington University School of Medicine
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Brain cells work differently than previously thought
2. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
3. New transfusion rules restrict donations from previously pregnant women
4. Z Trim Holdings Reports Restatement of Previously Issued Financial Statements; Amends Bylaws
5. CDC Reports Prevalence of Worms Transmitted by Dogs and Cats to Humans is Higher Than Previously Understood
6. China Sky One Medical Completes Previously Announced Amendment to 2006 Form 10KSB
7. Symmetry Medical Provides Update of Previously Disclosed Accounting Review at Sheffield, UK Operating Unit
8. More functional DNA in genome than previously thought
9. The Ensign Group, Inc. Acquires Assets of Three Previously Leased Facilities
10. HealthSouth Announces Final Agreement on Previously Disclosed Settlement with Federal Government
11. China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... For thirteen years, the Twin Cities DI ... event in the nation! This year, on May 5th, 2015, ... to take DI Day on the road by supporting the ... ChFC, RHU, DIA, CLTC, Chief Executive Officer at Secura Consultants ... the change by stating, "The first Twin Cities DI Day ...
(Date:4/24/2015)... California (PRWEB) April 24, 2015 Ryadon ... a wide range of capabilities and services to complement ... , Ryadon's Quantity Discount Program will be offered on ... follows: , Order 4-19: Receive 10% discount - Order ... by Using the Drawer Slides Products, ...
(Date:4/24/2015)... On February 21st, 2015, Per Wickstrom had the ... contributor Karen Salkin at Durkin Entertainment’s EcoLuxe Lounge, sponsored ... of which Wickstrom is the founder. Making appearances at ... EcoLuxe Lounge is a gathering of some of the ... and services. Among the many roles that she has ...
(Date:4/24/2015)... Integrative Therapeutics has introduced two new supplements focused ... A unique combination of herbs and nutrients, including ... apart from other antioxidant supplements. This formula relies ... versus the use of single or sequential compounds ... Alpha-Glycosyl Isoquercitrin, and Coenzyme Q10 with Setria® Glutathione. ...
(Date:4/24/2015)... National Access Cannabis (NAC), Canada’s provider ... cannabis, is taking a leadership role in ensuring Canadian ... NAC is the first to back mdBriefCase Group Inc.'s ... will be providing 300 healthcare professionals with free access ... Canadians gain safe and responsible access to medical cannabis ...
Breaking Medicine News(10 mins):Health News:Secura Consultants Takes DI Day On The Road 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3Health News:Karen Salkin Talks with Per Wickstrom at the 2015 EcoLuxe Lounge and the "Salute to the Oscars" Celebration 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 3Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 4Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2
... SOMERSET, N.J., Nov. 9 inVentiv Health Inc.,(Nasdaq: ... a new Client Development,and Integration team. The team will ... Chief Client Development Officer. The Client Development and ... segments to identify new opportunities to,serve both new and ...
... Interferon does not slow or halt the progression of ... who havent responded to previous attempts to eradicate the ... University School of Medicine participated has found. , Patients ... experience a significant decrease in viral levels and liver ...
... and techniques of soft condensed matter physics, a research team ... of attractions between proteins keeps the lens of the eye ... can cause proteins to aggregate and de-mix. This leads to ... could shed light on other protein aggregation diseases (such as ...
... after stopping the drug, researchers say , , FRIDAY, Nov. ... at a slightly increased risk for developing cervical cancer, ... very small risk disappears, a new British study suggests. ... women to continue getting screened for cervical cancer, experts ...
... 24 and Taclonex; Company ... financial guidance, ST. DAVID,S, Bermuda, Nov. 9 Warner Chilcott,Limited ... ended,September 30, 2007. Revenue in the quarter ended September 30, 2007 ... The,primary drivers of the increase in revenue were the net sales ...
... Global Commercialization, Program for Once-Daily Tramadol and Completion of Enrolment ... ... QC, Nov. 9 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS;,NASDAQ: DDSS) ... ended September 30, 2007. All figures are in Canadian dollars ...
Cached Medicine News:Health News:inVentiv Health Creates Client Development and Integration Team 2Health News:inVentiv Health Creates Client Development and Integration Team 3Health News:Interferon does not slow or stop hepatitis C from worsening, study finds 2Health News:Physics provides new insights on cataract formation 2Health News:Pill Poses Little Cervical Cancer Risk 2Health News:Pill Poses Little Cervical Cancer Risk 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 18Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 19Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 20Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 21Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 3Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 4Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 5Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 6Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 7Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 8Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 10
(Date:4/23/2015)... NORTH CHICAGO, Ill. , April 24, 2015 /PRNewswire/ ... U.S. Food and Drug Administration (FDA) has accepted its ... the company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ... is for the treatment of adults with chronic genotype ... AbbVie,s regimen is the first all-oral, interferon-free therapy being ...
(Date:4/23/2015)... Once again, BeaconMedaes is meeting healthcare facilities, ... safety. BeaconMedaes, priority is to partner with ... The next generation Zone Valve Box assembly strengthens ... mounted in the assembly, allowing for ease of sensor ... potentially releasing dust spores and other bacteria within the ...
(Date:4/23/2015)... April 23, 2015 Nektar Therapeutics (Nasdaq: NKTR ... ended March 31, 2015 on Thursday, April 30, 2015, after ... president and chief executive officer, will host a conference call ... (ET)/2:00 p.m. Pacific Time (PT). The press ... can be accessed through a link that is posted on ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
... NEW YORK, April 7, 2011 Reportlinker.com announces ... in its catalogue: European ... http://www.reportlinker.com/p0470760/European-Markets-for-Interventional-Cardiology-Devices-2011-15-Countries.html ... cardiology devices were valued at over euro1.5 billion. ...
... Reportlinker.com announces that a new market research report ... Global: Pharmaceuticals Industry Guide ... Guide is an essential resource for top-level data ... includes detailed data on market size and segmentation, ...
Cached Medicine Technology:Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 2Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 3Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 4Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 5Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 6Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 7Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 8Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 9Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 10Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 11Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 12Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 13Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 14Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 15Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 16Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 17Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 18Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 19Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 20Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 21Reportlinker Adds Global: Pharmaceuticals Industry Guide 2Reportlinker Adds Global: Pharmaceuticals Industry Guide 3Reportlinker Adds Global: Pharmaceuticals Industry Guide 4Reportlinker Adds Global: Pharmaceuticals Industry Guide 5Reportlinker Adds Global: Pharmaceuticals Industry Guide 6Reportlinker Adds Global: Pharmaceuticals Industry Guide 7Reportlinker Adds Global: Pharmaceuticals Industry Guide 8
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: